Pharming Group (PHGUF) Stock Price, News & Analysis

Company Overview

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders. Lead pipeline candidates include odiparcil for mucopolysaccharidosis type VI and investigational therapies aimed at chronic inflammatory and complement-mediated conditions. The company conducts clinical trials across multiple regions and collaborates with partners such as Chiesi and other specialty pharma organizations to advance its programs through regulatory review, manufacturing scale-up and commercial launch preparations.

Pharming Group’s operations span North America, Europe and select markets in Asia and Latin America, reflecting its global commercialization footprint. The company’s leadership team is headed by CEO Roy van den Berg, supported by a management team with extensive experience in biotechnology R&D, global regulatory affairs and specialty-product marketing. Pharming Group is listed on Euronext Amsterdam (symbol PHARM) and trades in the United States on the OTC market under the symbol PHGUF.

Key Stats

• Today's Range: $1.50 to $1.50
• 50-Day Range: $1.14 to $1.50
• 52-Week Range: $0.75 to $1.50
• Volume: N/A
• Average Volume: 868 shs
• Market Capitalization: $1.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PHGUF Stock Analysis - Frequently Asked Questions

How have PHGUF shares performed this year?

Pharming Group's stock was trading at $0.9815 on January 1st, 2025. Since then, PHGUF stock has increased by 52.8% and is now trading at $1.50.

How were Pharming Group's earnings last quarter?

Pharming Group NV (OTCMKTS:PHGUF) announced its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative trailing twelve-month return on equity of 3.31% and a negative net margin of 2.19%.

How do I buy shares of Pharming Group?

Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/05/2015
• Today: 9/09/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PHGUF
• Previous Symbol: OTC:PHGUF
• CIK: N/A
• Web: www.pharming.com
• Phone: (171) 524-7400
• Fax: 31-0-71-524-7445
• Employees: 382
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.84 million
• Net Margins: -2.19%
• Pretax Margin: 1.04%
• Return on Equity: -3.31%
• Return on Assets: -1.78%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 2.79
• Quick Ratio: 2.07

Sales & Book Value

• Annual Sales: $297.20 million
• Price / Sales: 3.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.33 per share
• Price / Book: 4.55

Miscellaneous

• Outstanding Shares: 671,070,000
• Free Float: N/A
• Market Cap: $1.01 billion
• Optionable: Not Optionable
• Beta: 0.63